At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
Verteporfin +1 moredrug
Likely dose
Verteporfin 6mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
In Brief
A Phase 2 clinical trial evaluating Verteporfin and ranibizumab for Chronic Central Serous Chorioretinopathy. Completed, enrolled 34 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the efficacy and safety of intravitreal ranibizumab injection versus low-fluence PDT in the treatment of chronic CSC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Central Serous Chorioretinopathy
CountriesSouth Korea
CollaboratorsNovartis Korea Ltd.
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedMar 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedMar 29, 2011
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 15.3 years ago
Interventions
Verteporfindrug
a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
ranibizumabdrug
Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months